↓ Skip to main content

Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study

Overview of attention for article published in European Urology Focus , June 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter
14 X users
facebook
2 Facebook pages

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study
Published in
European Urology Focus , June 2016
DOI 10.1016/j.euf.2016.06.001
Pubmed ID
Authors

Marco Moschini, Nicola Fossati, Akshay Sood, Justin K. Lee, Jesse Sammon, Maxine Sun, Dan Pucheril, Deepansh Dalela, Francesco Montorsi, R. Jeffrey Karnes, Alberto Briganti, Quoc-Dien Trinh, Mani Menon, Firas Abdollah

Abstract

Active surveillance (AS) is increasingly recognized as a recommended treatment option for prostate cancer (PCa) patients with clinically localized, low-risk disease; however, previous studies suggested that its utilization is uncommon in the United States. We evaluated the nationwide utilization rate of AS in the contemporary era. We relied on the 2010-2011 Surveillance Epidemiology and End Results (SEER) database using all 18 SEER-based registries. We identified 9049 patients that fulfilled the University of California, San Francisco AS criteria (prostate-specific antigen level <10ng/ml, clinical T stage ≤2a, Gleason score ≤6 [no pattern 4 or 5], and percentage of positive biopsy cores <33%). Logistic regression analysis tested the relationship between receiving local treatment and all available predictors. Only 32% of AS candidates did not receive any active local treatment. This proportion varied widely among the SEER-based registries, ranging from 13% to 49% (p<0.001). In multivariable analyses, clinical stage T2a (odds ratio [OR]: 1.23; p=0.04) and percentage of positive cores (OR: 1.10 for each 2% increase; p<0.001) were associated with a higher probability of receiving local treatment. Conversely, older age (OR: 0.89 for each 2-yr increase; p<0.001), not being married (OR: 0.64; p<0.001), and uninsured status (OR: 0.55; p=0.008) were associated with a lower probability of receiving active local treatment. The study is limited by the fact that SEER does not distinguish among patients undergoing observation, AS, watchful waiting, or initial hormonal therapy. In the United States, a considerable proportion of patients suitable for AS receive local treatment for PCa. Proportions differ significantly among SEER registries. Having more extensive and palpable disease, having medical insurance, being married, and being younger are associated with an increased probability of receiving local treatment for low-risk prostate cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 15%
Researcher 5 13%
Student > Bachelor 4 10%
Student > Doctoral Student 3 8%
Student > Postgraduate 3 8%
Other 8 21%
Unknown 10 26%
Readers by discipline Count As %
Medicine and Dentistry 12 31%
Nursing and Health Professions 3 8%
Computer Science 2 5%
Engineering 2 5%
Sports and Recreations 1 3%
Other 3 8%
Unknown 16 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 August 2017.
All research outputs
#4,093,922
of 25,374,917 outputs
Outputs from European Urology Focus
#514
of 1,440 outputs
Outputs of similar age
#68,649
of 368,451 outputs
Outputs of similar age from European Urology Focus
#15
of 46 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,440 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 368,451 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.